Perception to Hydroxyurea Therapy in Patients with Sickle Cell Disease: Report from 3 Centers

BACKGROUND: Hydroxyurea (HU) is an hemoglobin F inducing agent used in the treatment of sickle cell disease (SCD). AIM: The aim of this study is to determine the perception of HU by people living with SCD. MATERIALS AND METHODS: A pretested questionnaire was self-administered to known cases of SCD a...

Descripción completa

Detalles Bibliográficos
Autores principales: Korubo, Kaladada I., Onodingene, Nkemsinachi Maryanne, Okoye, Helen Chioma, Omunakwe, Hannah E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378460/
https://www.ncbi.nlm.nih.gov/pubmed/34213480
http://dx.doi.org/10.4103/aam.aam_36_20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378460/
https://www.ncbi.nlm.nih.gov/pubmed/34213480
http://dx.doi.org/10.4103/aam.aam_36_20

Ejemplares similares